Haemonetics Corporation (HAE) Stock Price & How to Invest

Haemonetics Corporation, based in Boston and listed on the NYSE, has sold blood-handling technology since 1971. Its largest business is plasma: the NexSys PCS apheresis machines, and the far more profitable single-use disposable kits that run on them, sit in the collection centers operated by companies like Grifols, Takeda's BioLife and Octapharma, which turn donated plasma into immunoglobulin and other plasma-derived therapies. A second business, grouped under the hospital umbrella, splits into Interventional Technologies (the VASCADE and VASCADE MVP vascular closure devices used after catheter procedures, plus the OpSens optical pressure sensing line and the Attune Medical esophageal cooling device) and Blood Management Technologies (TEG viscoelastic hemostasis analyzers, Cell Saver autotransfusion systems, and blood-tracking software). A third and shrinking business supplies whole-blood and apheresis collection to blood banks.

The investment picture for the past several years was dominated by one contract. CSL Plasma, historically Haemonetics' single biggest plasma customer, chose not to renew and moved to a competing device, and the transitional supply that followed rolled off through fiscal 2025, leaving a revenue headwind in the roughly $70 million to $100 million range that suppressed reported growth into fiscal 2026. That comparison is now behind the company. In the quarter ended June 2026, the first of fiscal 2027, revenue was about $339 million, up roughly 6% on both a reported and organic basis, with plasma up about 8% organically and the hospital businesses up about 6%, and management raised the full-year outlook to roughly 5% to 8% reported growth. At around $90.80 a share and about $4.1 billion of market value against roughly $1.35 billion of trailing revenue, the market is paying a little over three times sales for a business whose growth question has shifted from "can it replace CSL" to "how durable is what is left".

Customer concentration is the structural risk: plasma collection in the United States is consolidated into a handful of buyers, and the CSL departure showed how much revenue a single non-renewal can remove. Immunoglobulin demand has been reliable but is not guaranteed, and any move by a large customer toward in-house or competing collection hardware would repeat the problem. The interventional portfolio was assembled through three acquisitions in roughly two years, which leaves goodwill and intangibles on the balance sheet and convertible debt against them, and the pulsed field ablation transition has already demonstrated that a procedure-mix shift can cut into those products faster than the thesis assumed. The blood center business continues to decline as hospitals use less transfused blood, so mix has to keep improving just to hold consolidated growth flat. Tariffs, medical-device quality regulation and the pace of hospital capital budgets are the usual additional constraints on a company that manufactures physical disposables at scale.

10 analysts publish price targets on HAE, averaging $96.90 against a $90.80 price as of August 2026, or +6.7%. The published targets run from $86.00 to $105.00, a narrow spread, and the ratings split 8 buy, 3 hold, 0 sell. Over the last six months there have been 7 raises and 3 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full HAE forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Haemonetics Corporation. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Plasma without the CSL overhang. For the first time in several years, plasma revenue is being compared against a base that no longer contains the departed CSL volumes. The most optimistic published target, $105.00, assumes this works close to its best case.

The case against. Customer concentration is the structural risk: plasma collection in the United States is consolidated into a handful of buyers, and the CSL departure showed how much revenue a single non-renewal can remove. The most pessimistic target, $86.00, is roughly what HAE is worth if this bites instead.

Read the full bull and bear case on HAE, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Haemonetics Corporation's investor relations page or your broker.

• Market cap: ~$4.13B
• Revenue (TTM): ~$1.35B
• Share price: ~$90.80
• Price / TTM sales: ~3.1x
• Q1 FY2027 revenue (quarter ended June 2026): ~$339M, up ~6% organic
• FY2027 revenue growth guidance: ~5% to 8% reported, ~4% to 7% organic

A little over three times sales is an unremarkable multiple for a medical-device company with high-margin recurring disposables, and it reflects several years in which reported growth was held down by the CSL transition rather than by demand. The August 2026 print was the first quarter in a while where reported and organic growth were the same number, which is what happens when the lost contract finally leaves the comparison. What the multiple is really pricing is whether mid single-digit organic growth is the ceiling or the floor.

Other names that sit close to HAE: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get HAE exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so HAE sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where HAE fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

HAE is a niche medical-device compounder trading at a modest multiple, where the case rests on plasma volumes holding up and the interventional acquisitions delivering the growth they were bought for.

Whether HAE is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is HAE a buy or a sell?, and where the stock could go from here in the HAE stock forecast.

For income investors, whether HAE pays a dividend and how the payout looks is covered in does HAE pay a dividend? And to weigh HAE against a peer, read the full side-by-side comparisons: HAE vs CSL and HAE vs GRFS.